Development of a 177Lu-Labeled RGD Derivative for Targeting Angiogenesis

Abstract

Abstract Various Arg-Gly-Asp (RGD) derivatives have been labeled with various radioisotopes for targeting α(v)β₃ integrin, which is expressed during angiogenesis in tumor. In this study, 2-(4'-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA-SCN) and its c(RGDyK) conjugate (NOTA-SCN-c(RGDyK)) were labeled with ¹⁷⁷Lu, which is a near ideal radionuclide for treating tumors because it emits therapeutic beta particles and gamma rays for monitoring. ¹⁷⁷Lu (250 MBq) was labeled with 50 μg NOTA-SCN-c(RGDyK) quantitatively. The specific activity of ¹⁷⁷Lu-NOTA-SCN-c(RGDyK) was 1.44 × 10⁵ Ci/mol. Biodistribution study was performed in Balb/c mice xenografted with CT-26 (mouse colon cancer) cells. The highest uptake was found in kidneys (7.56% ± 0.71% ID/g at 1 hour), and tumor uptake was 1.70% ± 0.33% ID/g at 1 hour postinjection. Moderate tumor-to-blood (2.36 ± 0.29) and tumor-to-muscle (2.06 ± 0.40) ratios were observed. This study shows that ¹⁷⁷Lu-NOTA-SCN-c(RGDyK) is a potential therapeutic agent for angiogenic tumors, but special care is required to prevent kidney toxicity.